BTIG reiterates Buy on Boston Scientific, maintains $65 target
BTIG analyst Marie Thibault has reiterated a Buy rating for Boston Scientific, maintaining a price target of $65. The reiteration signals continued confidence in the company's performance and market position.
*this image is generated using AI for illustrative purposes only.
BTIG analyst Marie Thibault has reaffirmed a Buy rating for Boston Scientific, maintaining a price target of $65. The reiteration signals continued confidence in the company's performance and market position.
The rating and price target reflect the analyst's assessment of Boston Scientific's operational strength and future growth prospects. The $65 target provides a benchmark for investors evaluating the stock's potential upside.
Boston Scientific operates in the medical device sector, focusing on innovative solutions for various medical conditions. The company's product portfolio and market strategy are key factors influencing analyst ratings.
Analyst Rating and Target
| Metric | Value |
|---|---|
| Rating | Buy |
| Price Target | $65 |
| Analyst | Marie Thibault |
| Firm | BTIG |
The Buy rating suggests that the stock is expected to outperform the broader market. Investors may consider the maintained price target as an indicator of the stock's valuation potential.
What specific product launches or clinical trial results are expected to drive Boston Scientific's growth in the coming year?
How might competitive dynamics in the medical device sector impact Boston Scientific's ability to maintain its market position?
What regulatory challenges or approvals could influence the company's trajectory toward the $65 price target?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
